TORL BioTherapeutics, an antibody-drug conjugate (ADC) company led by former Celgene CEO Mark Alles, has successfully raised $96 million in Series C funding to advance its registrational trial focused on CLDN6-targeted therapies. This significant financial backing underscores the growing investor confidence in the ADC space, particularly as the demand for innovative cancer treatments continues to rise.
The funding will enable TORL to accelerate its clinical development efforts, positioning the company to potentially deliver new therapeutic options for patients with CLDN6-expressing tumors. The implications of this investment extend beyond TORL, as it highlights a broader trend in the biotech industry where ADCs are increasingly viewed as a promising class of therapeutics. As competition intensifies, companies in the sector will need to focus on differentiating their offerings and demonstrating clear clinical value to attract further investment and regulatory approval.
Use the database as your supply chain compass →
